News

Choice Equity Broking's report on Ajanta Pharma

AJP is currently in an investment phase, expanding its presence across geographies and therapeutic areas. As a result, the company expects higher promotional and employee expenses, which will likely cap EBITDA margin improvements until post-FY27E. Reflecting this outlook, we have revised our FY26E/FY27E earnings estimates downward by 6.2%/6.1%, respectively.

Outlook

However, we maintain our BUY rating on the stock and revise our target price to INR 3,180 (revised down from INR 3,667 in Q3FY25) by averaging our PE-based and DCF-based valuations. For the PE method, we apply a multiple of 30x on FY27E EPS, (in line with comparable generics peers in terms of growth, returns, and margins).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Ajanta Pharma - 02052025 - choice

Discover the latest Business News, Budget 2025 News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Stock Market Holiday Jammu Kashmir News Live Tim Cook Delhi Rain Heatwave in India Odisha 10th Result 2025 WB Madhyamik Result SSLC Result 2025 Kolkata News IPL Points Table 2025

Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups

Home Currencies Commodities Pre-Market IPO Global Market Bonds

Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance TrackerNew Fixed Deposits Fixed Deposit Comparison Fixed Income

Home MC 30 Top Ranked Funds ETFs Mutual Fund Screener

Income Tax Calculator EMI Calculator Retirement Planning Gratuity Calculator

Stock Markets

News18 Firstpost CNBC TV18 News18 Hindi Cricketnext Overdrive Topper Learning

About Us Contact Us Advisory Alert Advertise with Us SupportDisclaimer Privacy Policy Cookie Policy Terms & Conditions Financial Terms (Glossary) Sitemap Investors

You are already a Moneycontrol Pro user.